Novartis AG ADR (NVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novartis AG ADR (NVS) has a cash flow conversion efficiency ratio of 0.094x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.68 Billion) by net assets ($38.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novartis AG ADR (NVS) net asset quality to measure how much of total assets are equity-financed.
Novartis AG ADR - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Novartis AG ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Novartis AG ADR (NVS) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Novartis AG ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novartis AG ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LVMH Moët Hennessy - Louis Vuitton Société Européenne
PA:MC
|
0.118x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
|
Philip Morris International Inc
NYSE:PM
|
0.055x |
|
General Electric Company
SA:GEOO34
|
0.100x |
|
GE Vernova LLC
NYSE:GEV
|
0.344x |
|
PetroChina Co Ltd Class A
SHG:601857
|
0.068x |
|
Roche Holding AG
SW:ROG
|
0.296x |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
0.011x |
Annual Cash Flow Conversion Efficiency for Novartis AG ADR (1998–2025)
The table below shows the annual cash flow conversion efficiency of Novartis AG ADR from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see NVS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $46.55 Billion | $19.24 Billion | 0.413x | +3.53% |
| 2024-12-31 | $44.13 Billion | $17.62 Billion | 0.399x | +29.11% |
| 2023-12-31 | $46.75 Billion | $14.46 Billion | 0.309x | +29.09% |
| 2022-12-31 | $59.42 Billion | $14.24 Billion | 0.240x | +7.81% |
| 2021-12-31 | $67.82 Billion | $15.07 Billion | 0.222x | -7.75% |
| 2020-12-31 | $56.67 Billion | $13.65 Billion | 0.241x | -1.79% |
| 2019-12-31 | $55.55 Billion | $13.62 Billion | 0.245x | +35.24% |
| 2018-12-31 | $78.69 Billion | $14.27 Billion | 0.181x | +6.67% |
| 2017-12-31 | $74.23 Billion | $12.62 Billion | 0.170x | +10.97% |
| 2016-12-31 | $74.89 Billion | $11.47 Billion | 0.153x | -0.67% |
| 2015-12-31 | $77.12 Billion | $11.90 Billion | 0.154x | -21.36% |
| 2014-12-31 | $70.84 Billion | $13.90 Billion | 0.196x | +10.89% |
| 2013-12-31 | $74.47 Billion | $13.17 Billion | 0.177x | -13.73% |
| 2012-12-31 | $69.22 Billion | $14.19 Billion | 0.205x | -5.50% |
| 2011-12-31 | $65.94 Billion | $14.31 Billion | 0.217x | +7.63% |
| 2010-12-31 | $69.77 Billion | $14.07 Billion | 0.202x | -4.97% |
| 2009-12-31 | $57.46 Billion | $12.19 Billion | 0.212x | +9.54% |
| 2008-12-31 | $50.44 Billion | $9.77 Billion | 0.194x | +3.88% |
| 2007-12-31 | $49.40 Billion | $9.21 Billion | 0.186x | -11.60% |
| 2006-12-31 | $41.29 Billion | $8.71 Billion | 0.211x | -13.43% |
| 2005-12-31 | $33.16 Billion | $8.08 Billion | 0.244x | +22.89% |
| 2004-12-31 | $33.92 Billion | $6.72 Billion | 0.198x | -9.04% |
| 2003-12-31 | $30.52 Billion | $6.65 Billion | 0.218x | +6.21% |
| 2002-12-31 | $28.41 Billion | $5.83 Billion | 0.205x | +18.36% |
| 2001-12-31 | $25.56 Billion | $4.43 Billion | 0.173x | -15.86% |
| 2000-12-31 | $22.52 Billion | $4.64 Billion | 0.206x | +11.91% |
| 1999-12-31 | $23.55 Billion | $4.33 Billion | 0.184x | -2.48% |
| 1998-12-31 | $22.66 Billion | $4.28 Billion | 0.189x | -- |
About Novartis AG ADR
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more